Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000940328 | SCV001086189 | likely benign | not provided | 2024-07-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000940328 | SCV002002670 | uncertain significance | not provided | 2022-01-25 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In-silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002454154 | SCV002738781 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-25 | criteria provided, single submitter | clinical testing | The c.24C>T variant (also known as p.G8G), located in coding exon 1 of the NTHL1 gene, results from a C to T substitution at nucleotide position 24. This nucleotide substitution does not change the glycine at codon 8. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may result in the creation or strengthening of a novel splice donor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Center for Genomic Medicine, |
RCV003320223 | SCV004024282 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing |